Naloxone

Pain, Itching, Septic Shock + 7 more

Treatment

8 FDA approvals

20 Active Studies for Naloxone

What is Naloxone

Naloxone

The Generic name of this drug

Treatment Summary

Naloxone is a medication used to reverse the effects of opioid drugs, such as morphine, hydromorphone, methadone, heroin, and fentanyl. It works by blocking opioid receptors in the body and preventing opioids from having an effect. Naloxone is most commonly used to treat opioid overdoses, which can cause symptoms like difficulty breathing, reduced heart rate, slurred speech, drowsiness, and constricted pupils. It is available as an injection (brand name Narcan) or nasal spray, and is sometimes included in the combination product Suboxone with buprenorphine for the maintenance treatment of opioid

Narcan

is the brand name

image of different drug pills on a surface

Naloxone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Narcan

Naloxone

1971

241

Approved as Treatment by the FDA

Naloxone, otherwise called Narcan, is approved by the FDA for 8 uses including Pain and Opioid Dependence .

Pain

Used to treat moderate Pain in combination with Pentazocine

Opioid Dependence

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Pain

Used to treat Severe Pain in combination with Pentazocine

Opioid-Related Disorders

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Opioids

Respiratory Insufficiency

Effectiveness

How Naloxone Affects Patients

Naloxone is a medicine used to reverse opioid overdoses. It works quickly, but may need to be taken multiple times since it wears off sooner than opioids. It will not have any effect if the person has not taken opioids. When taking naloxone, people may experience withdrawal symptoms and the effects of the overdose may not be completely reversed if other drugs are present.

How Naloxone works in the body

Naloxone blocks opioids from binding to the body's opioid receptors. This reverses the effects of opioids and can be used to treat overdoses. If a patient has not taken opioids, naloxone won't have much of an effect.

When to interrupt dosage

The suggested dosage of Naloxone is contingent on the determined condition, such as Opioid Dependence, Pain and Septic Shock. The amount of dosage also varies as per the method of delivery (e.g. Spray, metered or Tablet) as detailed in the table below.

Condition

Dosage

Administration

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Itching

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioid-Related Disorders

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Septic Shock

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Respiratory Insufficiency

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Emergency Care

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Warnings

Naloxone Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Naloxone may interact with Pulse Frequency

There are 20 known major drug interactions with Naloxone.

Common Naloxone Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Naloxone.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Naloxone.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Naloxone.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Naloxone.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Naloxone.

Naloxone Toxicity & Overdose Risk

Naloxone has no significant effect on patients who have not taken opioids. The toxic dose of naloxone in mice and rats is greater than 1 g/kg when taken orally, 80 mg/kg when injected into the abdominal cavity, and 286 mg/kg when injected under the skin in mice, and 500 mg/kg when injected under the skin in rats.

image of a doctor in a lab doing drug, clinical research

Naloxone Novel Uses: Which Conditions Have a Clinical Trial Featuring Naloxone?

64 active clinical trials are underway to assess the effectiveness of Naloxone in providing relief from Opioids, Opioids-Induced Pain and Pain.

Condition

Clinical Trials

Trial Phases

Emergency Care

0 Actively Recruiting

Opioids

0 Actively Recruiting

Opioid-Related Disorders

0 Actively Recruiting

Septic Shock

0 Actively Recruiting

Respiratory Insufficiency

0 Actively Recruiting

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Pain

0 Actively Recruiting

Opioids

7 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1

Opioids

6 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Pain

0 Actively Recruiting

Naloxone Reviews: What are patients saying about Naloxone?

2

Patient Review

11/15/2007

Naloxone for Toxic Amount of Narcotics in the Body

I'm not a fan of needles, but this treatment was necessary.

1.7

Patient Review

10/3/2009

Naloxone for Decrease in Rate & Depth of Breathing due to Opioid Drug

My husband was given this drug due to a misdiagnosis. Unfortunately, it caused brain damage as I have been warned by other doctors. Please be careful with this medication.

1

Patient Review

7/27/2011

Naloxone for Decrease in Rate & Depth of Breathing due to Opioid Drug

The side effects of this drug are so severe that I would never recommend it to anyone, even if it was the only treatment available.

1

Patient Review

2/22/2011

Naloxone for Decrease in Rate & Depth of Breathing due to Opioid Drug

I was not pleased with the effects of this drug. They were very debilitating and I think it's wrong to give someone a medication without them knowing what it is first.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about naloxone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of opioid is naloxone?

"Naloxone is a drug that is used to counteract the effects of opioids. It works by attaching to the opioid receptors in the body and reverses the effects that other opioids have on the body. Naloxone can quickly restore normal breathing to a person if they have overdosed on opioids and their breathing has slowed or stopped."

Answered by AI

Is naloxone an opioid or opiate?

"The medication Naloxone is used to temporarily stop the effects of an opioid overdose, like slowed breathing. Increasing awareness and availability of this medication is a key way the public health system is responding to the opioid epidemic."

Answered by AI

What class of drug is naloxone?

"Naloxone injection is used to reverse the effects of opiates. It works by blocking the effects of opiates to relieve dangerous symptoms caused by high levels of opiates in the blood."

Answered by AI

What is the difference between Narcan and naloxone?

"Naloxone is an antidote for opioid overdose. People addicted to opioids are at heightened risk of overdose."

Answered by AI

Clinical Trials for Naloxone

Image of Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia in Vancouver, Canada.

Educational Interventions for Opioid Use in Dentistry

Any Age
All Sexes
Vancouver, Canada

The aim of this study is to estimate the impact of providing personalized prescribing data and educational materials on opioid prescribing to dentists in British Columbia, Canada. The main research questions are: 1. What is the impact of an intervention on the use of opioids for dental pain? The intervention includes a personalized prescribing report (a "Portrait"), brief educational summary, and patient education materials; and 2. Does the impact of the intervention increase when dentists are also invited to attend facilitated audit-and-feedback group sessions and to develop a practice improvement plan? Using administrative health data, the prescribing of those in different combinations of materials in the Early Group will be compared to those in the Delayed Group to estimate the impact of the materials on prescribing by the dentists.

Waitlist Available
Has No Placebo

Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia

Colin Dormuth, ScD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Have you considered Naloxone clinical trials?

We made a collection of clinical trials featuring Naloxone, we think they might fit your search criteria.
Go to Trials
Image of Toronto General Hospital in Toronto, Canada.

Transcutaneous Electrical Stimulation for Slow Breathing

18+
All Sexes
Toronto, Canada

After surgery, patients often recover in a special area called the Post Anesthesia Care Unit (PACU). Patients may receive pain medications either during the surgery or afterward in the PACU. While these medications are important for controlling pain, some of them can slow down breathing. To ensure patients' breathing remains safe, the nurses in the PACU monitor respiratory rate (how many breaths a patient takes per minute) and oxygen levels using standard monitoring equipment. This is the usual way they check for breathing concerns. If these monitors show that a patient's breathing has slowed down too much, nurses may wake the patient up or stimulate them using their voice or gentle physical touch to encourage deeper breaths. What is this study about? This research is testing a new approach that uses an additional monitor called capnography. Capnography helps detect slowing or stopping of breathing by measuring the carbon dioxide (CO2) exhaled by patients. If the monitor shows slowed or stopped breathing (called apnea, lasting at least 10 seconds), this study will test using a technology called transcutaneous electrical stimulation (TES) to encourage normal breathing. How does TES work? TES provides a slight, annoying sensation on the patient's skin-enough to wake them up without causing pain. This has been used in other studies to safely restore breathing after surgery. In this study, the researchers are testing whether a new automated device can deliver TES when the capnography monitor detects breathing issues. The goal is to test the feasibility (can this system work in the PACU?) and acceptability (how do patients feel about this approach?) of this technology. Who can join this study? Adults aged 18 or older who received general anesthesia and medications (opioids) for pain control during or after surgery are eligible. Patients recovering from surgery in the PACU at Toronto General Hospital may be invited to participate. Why is this study important? The study aims to reduce the risk of opioid-related breathing problems after surgery, making recovery safer and more comfortable for patients.

Recruiting
Has No Placebo

Toronto General Hospital

Have you considered Naloxone clinical trials?

We made a collection of clinical trials featuring Naloxone, we think they might fit your search criteria.
Go to Trials
Image of Pennsylvania Psychiatric Institute in Harrisburg, United States.

Semaglutide for Opioid Addiction

18 - 75
All Sexes
Harrisburg, PA

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

Phase 2
Recruiting

Pennsylvania Psychiatric Institute (+2 Sites)

Jennifer Nyland, PhD

Have you considered Naloxone clinical trials?

We made a collection of clinical trials featuring Naloxone, we think they might fit your search criteria.
Go to Trials